Mental state · patients with schizophrenia or related psychoses
1 finding from 1 review
Global impression ‐ no improvement ‐ medium term As defined in each study · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short/medium term Rate of attrition · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE HIGH DOSE may leads to lower leaving the study early ‐ short/medium term Rate of attrition compared with FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) (low certainty).
1 finding from 1 review
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short term Numbers requiring anticholinergic medication · patients with schizophrenia or related psychoses
1 finding from 1 review
Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Re‐admission during · Adults with acute asthma
Adults: higher dose/longer course showed no clear difference in re‐admission in compared with lower dose/shorter course (low certainty).
1 finding from 1 review
Asthma severity and symptoms · Adults with acute asthma
1 finding from 1 review
Asthma symptoms Complete resolution by day 28 · Adults with acute asthma
Adults: higher dose/longer course showed no clear difference in asthma symptoms Complete resolution by day 28 compared with lower dose/shorter course (low certainty).
1 finding from 1 review
Exacerbations · Adults with acute asthma
It is very uncertain whether adults: higher dose/longer course changes new exacerbation in compared with lower dose/shorter course (very low certainty).
2 findings from 1 review
FEV1 % predicted · Adults with acute asthma
1 finding from 1 review
All adverse events · Adults with acute asthma
It is very uncertain whether adults: higher dose/longer course changes all adverse events compared with lower dose/shorter course (very low certainty).
1 finding from 1 review
300/450 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in 300/450 IU vs 150 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
400/450 IU vs 300 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in 400/450 IU vs 300 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
IU vs 450 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in IU vs 450 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
Adverse effects (loose stools, diarrhoea) · Infants (primary teeth; baseline about 9 to 15 months)
1 finding from 1 review
Adverse effects were not reported in a usable format, but the reported rates of loose stools and diarrhoea were very similar between groups. There were no serious adverse effects during the study. Milgrom 2009.
1 study · 94 participants
GRADE not reported
Caries in primary teeth (mean number of decayed primary teeth) · Infants (primary teeth; baseline about 9 to 15 months)
1 finding from 1 review
Mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in adverse effects: 1. Extrapyramidal side effects (TESS) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Sedation/tranquillisation: Not sedated ‐ at four hours · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review